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Abstract
The poor healing capacity of cartilage and lack of effective treatment for associated disease and trauma makes it
a strong candidate for a regenerative medicine approach. Potential therapies tested to date, although effective,
have met with a number of intrinsic difﬁculties possibly related to limited autologous chondrocyte cell yield and
quality of cartilage produced. A potential mechanism to bypass limited cell yields and improve quality of differ-
entiation is to immortalize relevant cell types through the ectopic expression of telomerase. Pellet cultures of
human chondrocytes (OK3), bone marrow mesenchymal stem cells (BMA13), and embryonic stem cell (H1
line)-derived cells (1C6) and their human telomerase reverse transcriptase (hTERT) transduced counterparts
were maintained for 20 days in standard maintenance medium (MM) or transforming growth factor-b3-
supplemented prochondrogenic medium (PChM). Pellets were assessed for volume and density by microcom-
puted tomography. Quantitative gene expression (COL1A2, COL2A1, COL3A1, COL6A3, COL10A1, ACAN, COMP,
SOX9); sulfated glycosaminoglycans (sGAGs), and DNA quantiﬁcation were performed. Histology and immuno-
histochemistry were used to determine matrix constituent distribution. Pellet culture in PChM resulted in signif-
icantly larger pellets with an overall increased density when compared with MM culture. Gene expression
analysis revealed similarities in expression patterns between telomerase-transduced and parental cells in both
MM and PChM. Of the three parental cell types examined OK3 and BMA13 produced similar amounts of pellet-
associated sGAG in PChM (4.62 – 1.20 and 4.91 – 1.37 lg, respectively) with lower amounts in 1C6 (2.89 – 0.52 lg),
corresponding to 3.1, 2.3, and 1.6-fold increases from day 0. In comparison, telomerase-transduced cells all had
much lower sGAG with OK3H at 2.74 – 0.11 lg, BMA13H 1.29 – 0.34 lg, and 1C6H 0.52 – 0.01 lg corresponding to
1.2, 0.87, and 0.34-fold changes compared with day 0. Histology of day 20 pellets displayed reduced staining
overall for collagens and sGAG in telomerase-transduced cells, most notably with alterations in aggrecan and
collagen VI; all cells stained positively for collagen II. We conclude that while telomerase transduction may be
an effective technique to extend cellular proliferative capacity, it is not sufﬁcient in isolation to sustain a naive
chondrogenic phenotype across multiple cell types.
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Introduction
In the event of tissue damage, or as a result of degener-
ative disease processes, mature articular cartilage fails
to undergo adequate reparative processes as a result
of its hypocellular, avascular nature.1 As a consequence,
damage is persistent, with multiple joint tissues fre-
quently undergoing considerable further degeneration
culminating in osteoarthritis.2 Sufferers of osteoar-
thritis have a signiﬁcantly reduced quality of life due
to pain and loss of function, with a considerable con-
comitant social and economic burden.3 Treatment for
osteoarthritis and similar joint disorders is generally
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restricted to pain management strategies until the dam-
age is sufﬁciently extensive to warrant arthroplasty,4 al-
though in many smaller joints this may not be possible.
The lack of adequate regenerative or reparative pro-
cesses has long been described5; techniques associated
with the regenerative medicine ﬁeld, in particular the
use of transplantation-based cell therapies, may offer
hope for the treatment of cartilage defects, where cur-
rent standard therapies are inadequate. To date, vari-
ants of the autologous chondrocyte implantation/
transplantation procedure have been the most inten-
sively studied and have resulted in improvements in re-
pair, reductions in patient symptoms, and an improved
quality of life.6 Nevertheless, closer examination of the
cartilage repair site has shown that the tissue often does
not achieve optimal regeneration to hyaline cartilage.7,8
The underlying causes of poor hyaline cartilage regen-
eration have yet to be elucidated and would be of great
interest to the regenerative medicine community.
In vitro analysis of cellular differentiation processes
can provide valuable information which may then in-
form the likely outcomes of prospective regenerative
therapies. Unfortunately, the extensive study of pri-
mary cells, often used in such therapies, remains chal-
lenging due to the onset of replicative senescence in
an aging cell population most probably as a result of
progressive telomere shortening.9–11 This process is
further exacerbated by changes in cell phenotype as a
result of in vitro culture techniques; this is a particu-
larly well-established issue with the dedifferentiation
of primary chondrocytes12 and stress-induced senes-
cence.13 One possible technique to intervene in critical
telomere shortening and prevent phenotypic changes is
the re-expression of the catalytic subunit of telomerase
reverse transcriptase (human telomerase reverse tran-
scriptase [hTERT]) to stabilize or extend shortened
telomeres with the intended outcome of signiﬁcantly
extending the replicative lifespan of the cells, while si-
multaneously halting the phenotypic changes associ-
ated with cell aging.14–17
This study compared several metrics of chondrogen-
esis in pellet cultures of three human cell types (chondro-
cytes [OK3], mesenchymal stem cells [MSCs, BMA13],
and H1 embryonic stem cell [ESC]-derived MSC-like
cells [1C6]) with current or potential clinical applica-
tion for cartilage cell-based therapies and their hTERT-
transduced counterparts (OK3H, BMA13H, 1C6H).
These cells have previously been examined during ex-
pansion and in a simple chondrogenic monolayer differ-
entiation environment, where there were several changes
in cell phenotype, including diminished chondroge-
nic capacity in comparison to the more naive parental
cells.18 The present study utilized more biologically rel-
evant three-dimensional (3D) pellet cultures to com-
pare chondrogenesis across the three cell types and to
determine whether this was sufﬁcient to restore the
chondrogenic capacity of the transduced cells. Using
this technique we noted improved chondrogenesis in
OK3H cells in pellets compared with monolayer; how-
ever, overall chondrogenic capacity remained dimin-




Primary human knee articular chondrocytes OK3
(PromoCell, 71-year-old female), human MSCs BMA13,
H1 human embryonic stem cell (hESC)-derived MSC-
like cells, and the corresponding hTERT-transduced
cells OK3H, BMA13H, and 1C6H were previously
isolated/transduced as described.18,19 To isolate BMA13
cells, commercially sourced bone marrow aspirate
(Lonza) was seeded at a density of 1· 105 mononuclear
cells/cm2 in tissue culture ﬂasks precoated with 10 ng/mL
ﬁbronectin (Sigma) in phosphate-buffered saline (PBS).
Cells were seeded in high-glucose Dulbecco’s modiﬁed
Eagle’s medium (DMEM) (4.5 g/L glucose) suppleme-
nted with 5% (v/v) fetal bovine serum (FBS), 1% (v/v)
L-Glutamine (L-Glut), 1% (v/v) nonessential amino
acids (NEAA), and 1% (v/v) Penicillin/Streptomycin/
Amphotericin B (Lonza); a 50% media change was
performed after 7 days and a 100% media change at
14 days.20 BMA13 and OK3 underwent routine media
changes twice weekly with maintenance media (MM)
consisting of DMEM supplemented with 10% (v/v)
FBS, 1% (v/v) L-Glut, 1% (v/v) NEAA, and 4 ng/mL
basic ﬁbroblast growth factor (bFGF; PeproTech).21
1C6 were derived from the H1 ESC line as described
by Forsyth and McWhir.19 Brieﬂy, passage 72 H1
hESCs were plated in suspension culture to form em-
bryoid bodies for 96 h before being disaggregated and
plated on to gelatin-coated plates at clonal density.
Clone 1C6 cells had conﬁrmed expression of typical
MSC markers and tripotent (osteogenic, chondrogenic,
and adipogenic) differentiation. capacity19 Cells were
cultured in a MM of knockout-DMEM (Life Technolo-
gies) supplemented with 10% (v/v) FBS, 1% (v/v) L-Glut,
1% (v/v) NEAA, 4 ng/mL bFGF, and 100 nM dexa-
methasone (Sigma). A complete media change was
performed twice weekly. All cells were subcultured
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enzymatically at conﬂuence using 0.25% trypsin/
ethylenediaminetetraaceticacid (EDTA; Lonza). All
cells and pellets were cultured in humidiﬁed, 2% ox-
ygen, tri-gas-controlled incubators with 5% CO2 and
93% N2.
Transduction of cells with hTERT was achieved
using the Phoenix-A (Amphotropic) system with a
pBABE-hTERT construct. BMA13 were transduced at
passage 2, OK3 at passage 4, and 1C6 at population
doubling 36. Selection of transduced cells was per-
formed with 1mg/mL G418.18
Chondrogenic differentiation
Pellets were created by centrifuging 2.5· 105 cells/pellet
in 1mL of media at 300 g for 3min in 1.5-mL micro-
centrifuge tubes. Pellets were formed and cultured in
their standard MM and in prochondrogenic medium
(PChM) consisting of the cells’ MM with reduced
FBS (1% [v/v]), further supplemented with 10 ng/mL
transforming growth factor (TGF)-b3 (PeproTech),
0.1 lM dexamethasone, 40 lg/mL L-proline (Sigma),
50 lM ascorbic acid phosphate (Sigma), 1% (v/v) insu-
lin, transferrin, selenium (Sigma), and 1% (v/v) sodium
pyruvate (Sigma). Pellets were cultured for 20 days with
twice weekly media changes. Pellets were ﬁxed and
used at days 1 and 20 for microcomputed tomography
(lCT) analysis and histology, and either frozen at
80C, or processed immediately at days 0 and 20
for sulfated glycosaminoglycans (sGAGs), DNA, and
gene expression quantiﬁcation. Spent culture media
were also processed for sGAG quantiﬁcation.
Microcomputed tomography
Pellets were ﬁxed in 4% (w/v) paraformaldehyde over-
night before being stored in PBS at 4C. Immediately
before scanning, samples were brieﬂy blotted to remove
excess PBS and scanned using a Scanco Medical lCT
40 scanner at 45 kVp/176 lA. For volume and density
analysis, images were thresholded at a lower threshold
value of 50 and the maximum upper threshold value
of 1000.
Pellet histology and immunohistochemistry
Pellets were ﬁxed in 4% (w/v) paraformaldehyde
overnight, serially dehydrated (70% [v/v] industrial
methylated spirits, 90% [v/v] isopropanol, 100% [v/v]
isopropanol, 100% [v/v] isopropanol), and embedded
in parafﬁn wax. Blocks were sectioned at 10lm, dew-
axed and stained with Toluidine Blue (0.04% [w/v] Tol-
uidine Blue in 0.2M sodium acetate buffer), Picrosirius
Red (0.1% [w/v] Picrosirius Red in saturated aqueous
picric acid), and Hematoxylin and Eosin.
Sections for immunohistochemistry were dewaxed
and antigen retrieval through heat-induced epitope
retrieval in citrate buffer (pH 6) or enzymatic antigen
retrieval (0.1% trypsin) was performed. Sections were
blocked with 1% (w/v) bovine serum albumin for 1 h
and incubated with the primary antibodies (collagen
I, collagen II, collagen VI, collagen X, and aggrecan
[Abcam]) overnight followed by processing with the
appropriate secondary antibody ABC Immunoperoxi-
dase Staining Kit (Santa Cruz Biotechnology).
Dimethylmethylene blue sGAG and PicoGreen
DNA quantiﬁcation
For sGAG and DNA quantiﬁcation, pellets and cumu-
lative media were used at days 0 and 20. Pellets and
media aliquots were digested by overnight incubation in
100lL of 2.5mg/mL proteinase K (Sigma) in 100mM
ammonium acetate (Sigma) at 57C with periodic vortex-
ing. Following digestion, 1mL of ice-cold ethanol was
added to each digest and samples left to precipitate over-
night at20C. Samples were pelleted at 17,000 g, the eth-
anol was removed, and samples air dried before being
resuspended in 100mM ammonium acetate for analysis.
For sGAG quantiﬁcation, 200 lL of dimethylmethy-
lene blue (DMMB) solution (64.0 lg/mL DMMB,
3.0mg/mL glycine, 2.4mg/mL NaCl, all dissolved in
0.01MHCl [all Sigma])22 was dispensed to the samples
in 96-well microplates using an automated dispenser.
Absorbance values were obtained immediately at 530nm
using a Synergy-2 plate reader (BioTek). Concentra-
tions were determined using a bovine chondroitin sul-
fate (Sigma) concentration curve.
The Quant-iT PicoGreen double-stranded DNA
assay (Life Technologies) was carried out according
to the manufacturer’s protocol. Duplicate sample ali-
quots were diluted 1 in 10 in Tris EDTA buffer in
96-well microplates before incubation with PicoGreen
working solution in the dark. Plates were read using
a Synergy-2 plate reader (excitation 480 nm, emission
520 nm). Concentrations were determined using a
lambda DNA calibration curve.
Gene expression analysis
Pellets were lysed and RNA extracted using the Qiagen
RNeasy Mini Kit. Pellets were ﬁrst physically disrupted
using disposable, single-use pestles in the presence of
a small amount of RLT lysis buffer supplemented
with 10lL/mL b-mercaptoethanol. To further disrupt
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proteinaceous material, 150 lL of 2.5mg/mL protein-
ase K23 was added to the lysis buffer and samples incu-
bated for 20min at 57C with vortexing. The resulting
lysate was added to a QIAshredder and centrifuged at
17,000 g before the minispin column was discarded
and the tube capped. All lysates were immediately pro-
cessed for RNA extraction as per the manufacturer’s
protocol. Eluted RNA was quantiﬁed with a NanoDrop
2000 spectrophotometer (Thermo Scientiﬁc) and
stored at 80C until required.
Relative gene expression in cell pellets at day 0 and
after 20 days in either MM or PChM was assessed using
quantitative reverse transcription–polymerase chain reac-
tion (qRT-PCR) with the SuperScript III Platinum SYBR-
Green OneStep qPCR Kit (Life Technologies) and a
Stratagene MX3005P real-time thermal cycler.
Statistical analysis
Data are expressed as mean– standard deviation unless
otherwise indicated. qRT-PCR data were analyzed
using REST-2009 with signiﬁcance determined using a
randomization algorithm.24 Hierarchical clustering was
performed using the Hierarchical clustering algorithm
in Gene Cluster 3.025 using an uncentered correlation
similarity metric and average linkage clustering with as-
sociated data viewed in Java TreeView.26 Statistical anal-
ysis of pellet size, DNA content, and sGAG production
was by repeated measures two-way analysis of variance
with Bonferroni post-tests of chondrogenic supplemen-
ted samples compared with nonsupplemented controls
using GraphPad Prism 5.00 (GraphPad, San Diego,
CA). Results were deemed to be statistically signiﬁcant
when p £ 0.05.
Results
Pellets could be formed in all conditions,
but showed a strong reliance on a prochondrogenic
environment for maintenance
Stable, free-ﬂoating pellets were formed in both MM and
PChM within a 24-h period. lCT imaging of day 1 pel-
lets (Fig. 1A) showed a process of folding or rolling of the
multilayered, concave, sheet of cells formed by centrifu-
gation, frequently resulting in a hollow core to the pellets.
Over the 20-day time course early features caused by the
folding process generally resolved with pellets having a
more spheroidal, homogeneous appearance; early het-
erogeneity was more likely to persist in MM cultures.
The use of lCT enabled quantitative assessment of
pellet volume and density. All pellets were found to
be smaller at day 20 than day 1 (Fig. 1B). The decrease
in size was always larger in MM cultures (0.061–
0.479· day 1) than in PChM (0.272–0.837 · day 1),
such that by day 20 all pellets cultured in PChM were
signiﬁcantly larger than the corresponding MM cultures
(Fig. 1C). In all cell types there was a smaller reduction
in size in parental cell MM cultures compared with
transduced MM cultures. With the exception of 1C6H
pellets, culture in PChM also resulted in a trend for
the formation of denser cell pellets (Fig. 1D) with this
difference becoming signiﬁcant in OK3H ( p£ 0.001),
BMA13 ( p£ 0.0001), and 1C6 ( p£ 0.05) (Fig. 1E).
Pellet culture, media type, and hTERT transduction
result in alterations in gene expression
Figure 2 shows relative fold change in gene expres-
sion in a panel of representative chondrogenic and
hypertrophy/ﬁbrocartilage markers (COL1A2, COL2A1,
COL3A1, COL6A3, COL10A1, ACAN, COMP, and
SOX9). Overall, although pellets displayed considerable
heterogeneity in expression level, each cell type had
similar patterns of gene expression in both MM and
PChM, generally with a more muted response in
MM, indicating a chondrogenic response induced by
3D culture in the absence of biochemical cues. Trans-
duced population responses were similar overall to
those of the parental cells. Chondrocytes and hESC-
derived cells tended strongly toward upregulation in
gene expression; with a single gene, COL2A1, sig-
niﬁcantly downregulated across all eight conditions
( p £ 0.05). In contrast, MSCs, particularly BMA13H
displayed a much stronger differential response to cul-
ture conditions with a greater trend for downregulation
in MM (BMA13: 3/8 [COL2A1, COL3A1, ACAN]
genes, BMA13H: 7/8 [COL1A2, COL2A1, COL3A1,
COL6A3, COL10A1, COMP, SOX9]) genes, and upre-
gulation in PChM (BMA13: 4/8 [COL1A2, COL6A3,
COL10A1, COMP] genes, BMA13H: 5/8 [COL1A2,
COL3A1, COL6A3, COL10A1, COMP] genes).
Interestingly, the transcription factor SOX9, consid-
ered the master regulator for chondrogenesis, was sig-
niﬁcantly ( p £ 0.05) upregulated in OK3, OK3H, 1C6
and 1C6H in both media types at day 20 in contrast
to the MSCs BMA13 and BMA13H where levels were
not signiﬁcantly different to day 0 cultures. Another
of the paradigm markers for hyaline cartilage produc-
tion ACAN was up-regulated in OK3, 1C6 and 1C6H
pellets ( p £ 0.05) while being strongly down-regulated
in the primary MSCs BMA13 ( p £ 0.05) and static in
the transduced BMA13H pellets. COL2A1 expression
was up-regulated in OK3 MM cultures ( p £ 0.05) but
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remained unchanged, relative to day 0, in OK3 PChM,
OK3H MM and PChM, BMA13H PChM, 1C6 MM
and PChM or was down-regulated in all other cultures
(BMA13 MM and PChM, BMA13H MM, 1C6H MM
and PChM) ( p £ 0.05). Markers for ﬁbrocartilage pro-
duction and hypertrophy, COL1A2 and COL10A1,
were also frequently upregulated with COL1A2 upre-
gulation ( p £ 0.05) in all parental cell pellet cultures
with the exception of BMA13 MM. In contrast, trans-
duced pellets were less likely to express COL1A2 with
signiﬁcant upregulation noted in one transduced pel-
let condition only (BMA13H PChM). COL10A1 was
upregulated in all parental cell cultures, OK3H in both
MM and PChM and BMA13H PChM ( p £ 0.05).
BMA13H MM samples displayed signiﬁcant downre-
gulation in line with the downregulation noted in all
other genes with this sample.
Patterns of gene expression were explored quantita-
tively using a hierarchical clustering algorithm (Fig. 3).
The strongest correlations in gene expression proﬁles
were found with the chondrocytes and the hESC-
derived cells (clusters 1–6, correlation coefﬁcients [q]
of >0.8). Primary chondrocytes OK3 clustered strongly
with primary hESC-derived cells 1C6 in both MM
(cluster 2, q 0.96) and PChM (cluster 3, q 0.96) condi-
tions, whereas the transduced variant of these cell types
OK3H (cluster 1, q 0.97) and 1C6H (cluster 4, q 0.94)
clustered most strongly by cell type irrespective of
media formulation. BMA13 and BMA13H showed
similarities in expression in PChM (cluster 7, q 0.8).
In MM, however, BMA13 clustered weakly with the
other day 20 samples (cluster 14, q 0.37), whereas
BMA13H clustered with day 0 OK3H PChM samples
(cluster 8, q 0.78).
FIG. 1. PChM supports stability and promotes increased pellet size. (A) lCT scans postﬁxation of day 1 and
20 pellets in MM or PChM indicate that pellets are formed by ﬂattened, multilayered cell sheets folding or
rolling to form spheroids. (B) Fold change in pellet volume relative to day 1. (C) Pellet volume at day 20.
(D) Fold change in pellet density relative to day 1. (E) Pellet density at day 20. PD level for cells was as follows:
OK3 PD6, OK3H PD50, BMA13 PD1, BMA13H PD16, 1C6 PD36, and 1C6H PD107. **p < 0.01, ***p < 0.001,
****p < 0.0001. Y-axis on (B) and (D) indicate fold change at day 20 relative to day 1, (C) pellet volume (mm3),
(E) pellet density (relative units). Data are plotted as mean – standard deviation, n = 3. lCT, microcomputed
tomography; MM, maintenance medium; PChM, prochondrogenic medium; PD, population doubling.
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FIG. 2. Pellet culture, media type, and hTERT transduction inﬂuence gene expression. Box and whisker plots
indicating relative gene expression at day 20 determined using 2DDCT with expression relative to the same-cell
day 0 MM sample. (A) OK3 PD6. (B) OK3H PD50. (C) BMA13 PD1. (D) BMA13H PD18. (E) 1C6 PD36. (F) 1C6H
PD107. *p£ 0.05. In all cases the Y-axis represents 2DDCT, the box represents the interquartile range, the whiskers
the outer quartiles, and the line the median expression. hTERT, human telomerase reverse transcriptase.
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hTERT transduction reduced sGAG production
DMMB analysis showed higher sGAG content in pel-
lets cultured in PChM than MM, achieving statistically
signiﬁcant levels in all but BMA13H pellets (Fig. 4A,
B). Parental cell pellets cultured in PChM always con-
tained more sGAG than their transduced counterparts
(OK3 4.62– 1.20lg, OK3H 2.74– 0.11lg, BMA13 4.91–
1.37 lg, BMA13H 1.29 – 0.34 lg, 1C6 2.89 – 0.52 lg,
1C6H 0.52– 0.01lg) as the transduced cells had only
small gains, or losses, being particularly evident in
FIG. 3. Hierarchical clustering highlights similarities in gene expression in MM and PChM and between
chondrocytes and human embryonic stem cell-derived cells. Samples (excluding day 0 MM) were subjected
to hierarchical clustering to identify sample group correlations in expression patterns. Red indicates
upregulated genes, green downregulated genes, and black no change in expression. All expression changes
are determined relative to the day 0 MM condition. PD level of cells is as follows: OK3 PD6, OK3H PD50,
BMA13 PD1, BMA13H PD18, 1C6 PD36, and 1C6H PD107. Correlation coefﬁcients for each cluster are listed
below the heatmap.
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FIG. 4. hTERT transduction reduced sGAG production compared with parental cells. sGAG and DNA content
in pellets was quantiﬁed at day 0 and at day 20 after culture in MM or PChM for all cell pellets. (A) Absolute
pellet- and media-associated sGAG at day 20. (B) Fold change in pellet-associated sGAG at day 20 relative
to day 0. (C) Pellet DNA content at day 20. (D) Fold change in pellet DNA content at day 20 relative to day 0. (E)
Pellet and media day 20 sGAG normalized to day 20 DNA content. (F) Fold change in normalized day 20
sGAG content relative to day 0 levels. PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD6,
BMA13H PD16, 1C6 PD36, and 1C6H PD86. *p£ 0.05, **p£ 0.01, ***p£ 0.001, ****p£ 0.0001. The Y-axes on (A) and
(C) indicate sGAG and DNA quantity (lg) and (B) and (D) fold change in sGAG and DNA, respectively. The
Y-axis on (E) represents sGAG normalized to DNA content (lg/lg) and on (F) fold change in normalized sGAG
relative to day 0 levels. Data are plotted as mean– standard deviation, n=3. sGAG, sulfated glycosaminoglycan.
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1C6H pellets, where sGAG levels decreased to only
0.22 and 0.34 · day 0 amounts in MM and PChM, re-
spectively. Media sGAG levels were also determined
and were found to be highest in chondrocyte-based
cultures.
Pellet DNA content decreased in all MM cultures;
PChM cultures generally maintained a DNA content
much closer to day 0 levels resulting in pellets with
more DNA following culture in PChM compared
with MM, signiﬁcantly so in all but BMA13. OK3H-
transduced cells appeared to be particularly tolerant
of MM culture, with much smaller reductions in
DNA compared with the parental OK3 cells (0.91 vs.
0.25 · day 0). As with sGAG, reductions in DNA levels
were particularly dramatic in 1C6H at only 0.13 and
0.21 · day 0 levels in MM and PChM.
Normalization of pellet sGAG to DNA maintained
previously observed absolute sGAG trends across OK3,
OK3H, BMA13, and BMA13H. In PChM BMA13
remained the highest sGAG producer at 2.23 – 0.31
lg/lg followed by OK3 with 1.87 – 0.41 lg/lg, and ﬁ-
nally 1C6 with 1.13 – 0.29 lg/lg. OK3H and BMA13H
were reduced in comparison with 1.45 – 0.03 lg/lg and
0.46 – 0.14 lg/lg, respectively. These values remained
signiﬁcantly higher than those obtained for pellets cul-
tured in MM with the difference greatest in BMA13
followed by OK3, and OK3H. BMA13H, 1C6, and
1C6H cell pellets cultured in PChM were not signiﬁ-
cantly different to MM cultures and most strikingly,
normalized levels in 1C6H were similar to 1C6 levels
at 1.20 – 0.15 lg/lg and 1.16– 0.03 lg/lg and in MM,
and 1.18 – 0.08 lg/lg and 1.13 – 0.29 lg/lg in PChM
due to large losses in both sGAG and DNA as a result
of pellet instability.
hTERT transduction reduces overall collagen
and sGAG extracellular matrix staining
Histological analysis (Fig. 5) of parental cells showed
more variability in staining between culture in MM
and PChM than transduced cells. OK3 and BMA13
pellets cultured in MM had minimal intercellular stain-
ing for cartilaginous extracellular matrix (ECM) com-
ponents; although OK3 appeared to develop a slightly
more matrix-rich capsule, BMA13 pellets in MM
were poorly formed and very friable upon sectioning.
Notably, 1C6 pellets in MM, while being smaller than
those cultured in PChM, were very similar in ECM
content to PChM cultures. The culture of all parental
cell pellets in PChM resulted in larger, more ECM-
rich pellets with positive staining for both collagen
and sGAG. Collagen ﬁbers in OK3 pellets were ﬁner
and more homogeneously distributed, whereas BMA13
and 1C6 stained more intensely for collagen that was
more heterogeneously distributed within the pellet.
Crosspolarized images (inset) of BMA13 revealed ﬁbers
that were almost exclusively yellow to red, indicative
of large, organized ﬁbers27 with few of the ﬁner green
ﬁbers that were present in 1C6 pellets. Toluidine Blue
staining for sGAG followed a very similar pattern with
intense metachromatic staining of sGAG in BMA13
pellets, corresponding with areas of high collagen depo-
sition, while being more diffuse and homogeneous in
OK3 and 1C6 pellets. Transduced cells, OK3H and
BMA13H, behaved dissimilarly to parental counter-
parts, forming larger more stable pellets; however, only
minimal matrix staining was observed.
hTERT transduction reduced collagen VI
and aggrecan incorporation into the ECM
Immunoperoxidase staining (Fig. 6) for ECM proteins
generally agreed with previous data; staining tended to
be more pronounced in primary pellets and PChM
than transduced counterparts and MM. The most
prominent ECM molecules were collagen II, particu-
larly pericellularly, and collagen VI; despite upregula-
tion at the gene level only low levels of collagen I
staining were detected. Marked aggrecan staining was
restricted to OK3 cultures particularly in PChM and
BMA13 in PChM, where staining was well deﬁned
and mirrored Toluidine Blue staining. Type X collagen
was most evident in BMA13 MM pellets, where stain-
ing was regional, and to a lesser extent BMA13 PChM
and 1C6 MM cultures; more subtle staining was evi-
dent in all other cultures.
Discussion
Cell immortalization through the constitutive expres-
sion of hTERT to extend the proliferative potential of
primary cells in vitro while maintaining a naive chon-
drogenic phenotype is an appealing prospect. We have
previously shown that this approach can extend prolif-
erative potential, including to the point of apparent im-
mortality, but chondrogenic capacity is reduced during
growth factor-induced monolayer chondrogenesis.18
We have now extended those observations using a
pellet culture system to provide additional spatial dif-
ferentiation cues that are believed to be beneﬁcial to
chondrogenesis,28–30 particularly in conjunction with
reduced oxygen culture,31,32 to determine whether this
was sufﬁcient to ameliorate the loss in differentiation
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capacity previously seen. Despite introducing these
modiﬁcations, we found that while all cells responded
differentially to MM versus PChM, chondrogenesis
was reduced in all hTERT-transduced cell populations.
All cells readily formed pellets and these were consis-
tently larger with sustained DNA levels and increased
sGAG after culture in PChM compared with MM. In
the absence of biochemical prochondrogenic stimuli
provided by PChM standard MM was generally unable
to support long-term pellet stability, nor cell prolifera-
tion. This has signiﬁcant treatment implications as
transplantation of cells to an environment lacking ade-
quate prochondrogenic stimuli is likely to lead to poor
clinical outcomes. 1C6H performed particularly badly,
most likely as a result of the transduction process, as
the parental 1C6 cells formed stable pellets in PChM
and in contrast to OK3 and BMA13, in MM. The 1C6
MM contains dexamethasone, which may be responsi-
ble for stabilizing the pellets and supporting a limited
amount of chondrogenesis.33 This suggests that the ad-
ministration of dexamethasone, either through the in-
corporation of drug-releasing scaffold or systemically,
to patients receiving a cartilage cell therapy treatment
may be beneﬁcial; however, the results from preliminary
animal studies are varied.34,35
Immortalized cell lines are generated to provide a
long-term supply of cells with a stable phenotype for
in vitro studies; however, the outcomes have been
FIG. 5. hTERT transduction reduced ECM staining for both sGAG and collagen. Histological staining of 10 lm-
sectioned pellets at day 20 after culture in MM or PChM as indicated. Sections are stained with Hematoxylin
and Eosin (upper); Picrosirius Red for collagen (middle); inset images are acquired under crossed polarizers;
and Toluidine Blue (lower). PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H PD16,
1C6 PD36, and 1C6H PD86. PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13 PD6, BMA13H
PD16, 1C6 PD36, and 1C6H PD86. Scale bar = 100 lm.
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FIG. 6. hTERT transduction reduced collagen VI and aggrecan incorporation into the ECM. Immunoperoxidase
staining of 10lm-sectioned pellets at day 20 after culture in MM or PChM as indicated. Sections were stained
for collagen types I, II, VI, and X, and aggrecan. PD level for cells was as follows: OK3 PD6, OK3H PD50, BMA13
PD6, BMA13H PD16, 1C6 PD36, and 1C6H PD86. Scale bar = 100 lm. ECM, extracellular matrix.
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varied.14,36–50 The underlying variation in response has
yet to be explained, however, a number of factors may be
contributing. Studies examining variation in cell response
at a single cell level using clonal populations have found
that there are differences in outcome. This may be inﬂu-
enced by the variation in the starting cell population,
for example MSCs are known to be a mixture of cells
with varied potency51,52; similarly chondrocytes dis-
play differences in differentiation capacity,53 perhaps
depending on their tissue zone of origin.54
The extensive expansion of cells, particularly in poly-
clonal populations, favors the selection of cells with
high proliferative capacity. There is evidence that ‘‘cell
competition’’55 may lead to slowly proliferating clones
arising during cell culture to be eliminated by apopto-
sis when in direct contact with faster growing cells.56
The concept that more proliferative cells are less likely
to undergo differentiation has merit; the two processes
of proliferation and differentiation are exclusive, with
cells developing and exhibiting the features of a differ-
entiated phenotype during interphase.57 Cells that spend
less time in interphase due to more rapid cell cycling are
therefore less likely to exhibit the features associated
with a differentiated phenotype. The rapidly prolifer-
ating 1C6 cells and the more extensively expanded
transduced cells all appear to have a less differentiated
phenotype. One possibility to ‘‘rescue’’ cells that are
more proliferative to potentially increase their differ-
entiation capacity is the application of conditional or
transient immortalization. Transient rather than con-
stant expression of hTERT is sufﬁcient to extend cellular
lifespan and conditional or transient immortalization
has been successfully used in several cell types, including
ﬁbroblasts,58 MSCs,59 beta cells,60 and chondrocytes.61
Interestingly overexpression of hTERT in the undif-
ferentiated H1 hESC cell line, the parental line of 1C6,
has independently been found to affect the differentia-
tion capacity of the cells with reduced expression of
germline markers and increased expression of the pluri-
potency marker OCT4.37 If 1C6 does not reﬂect a fully
differentiated MSC-like cell, it is possible that the results
herein represent a very similar response and explain
why ectopic expression in 1C6H resulted in very poor
differentiation. Despite the more muted chondrogenesis
seen in 1C6 the sustained upregulation of genes associ-
ated with chondrogenesis, including SOX9, suggests that
these cells may have a further capacity for chondrogen-
esis with additional differentiation cues. This is perhaps
unsurprising when the complex routines employed for
hESC chondrogenic differentiation62,63 are compared
with the relatively simple PChM used in this study.
An independent report on the chondrogenic capacity
of another H1-derived, MSC-like cell type in comparison
to MSCs yielded similar results to those herein. The re-
sponse of the cells in that case was improved by the ad-
dition of BMP7 to cultures64 and this may be an option
in future work.
In contrast to 1C6 and OK3 BMA13 had signiﬁcant
downregulation of the majority of chondrogenesis-
associated genes, including SOX9. MSCs are prone to
osteogenesis when implanted ectopically65 and there
is no evidence as yet that they spontaneously form
any other lineage-speciﬁc tissue type in the absence of
the appropriate prodifferentiation stimulus.66 It has
also been suggested that MSCs may experience a lag
period before the onset of differentiation due to their
stem cell state67 and extended culture has proved bene-
ﬁcial in some cases.33,68 Nevertheless, our results would
suggest that this is not the case here as the MSCs pro-
gressed rapidly through a chondrogenic phase, where
aggrecan was deposited to hypertrophy associated with
downregulation of theACAN and SOX9 genes and upre-
gulation of type I and type X collagen. These results are
typical for both chondrocytes and MSCs and support
much of the available literature.33,69–71 Further reﬁne-
ment of prochondrogenic culture conditions is ongo-
ing.71 However, factorial screening of growth factor
supplementation on an array of ‘‘wanted’’ and ‘‘un-
wanted’’ genes associated with chondrogenesis found
no combination in which optimal gene expression for
chondrogenesis of MSCs could be achieved, with both
wanted and unwanted genes upregulated simultaneous-
ly; the study concluded that TGF-b1, 2, or 3 combined
with dexamethasone supplementation still provided the
overall best outcome.72 Alternative sources of MSCs, in-
cluding those residing in the joint compartment, may
provide cells more suited to chondrogenesis and there
has been a recent interest in the application of synovial
MSCs73 and cells from the infrapatellar fat pad74 as alter-
natives to bone marrow.
Biochemically, both the OK3 and BMA13 pellets in
PChM were similar with respect to sGAG accumula-
tion; however, while OK3 sGAG and collagen deposi-
tion was homogeneous, BMA13 evidenced a distinct
regional pattern of sGAG staining that was mirrored
by aggrecan and collagen deposition. Regional varia-
tions in matrix deposition have previously been attrib-
uted to biochemical gradients; however, the pattern of
staining seen with BMA13 mirrors the folded pellet
shape seen by lCT analysis. During pellet formation
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the cells on the periphery of centrifuged pellets are ex-
posed to higher tension mediating changes in the
cell cytoskeleton and morphology; these changes can
induce signiﬁcant downstream effects on cell behav-
ior, including inﬂuencing cell differentiation. Higher
stresses can inﬂuence MSCs such that they are directed
more toward the osteogenic lineage.75 Studies where
centrifuged cell pellets are compared with naturally ag-
gregated micromasses report more optimal results
in the micromasses indicating that the centrifugation
technique impacts on the subsequent cell biology
even within the same population.76,77 The overall result
of this is that while biochemical cues remain important,
cells are also receiving potentially competing cues as a
result of mechanical forces and spatial patterning. The
results herein suggest that MSCs may be more sensitive
than the chondrocytes to these competing cues, proba-
bly due to their multipotent nature.
Conclusion
In the presence of prochondrogenic cues, stable pellets
undergoing chondrogenesis were formed from all pa-
rental cell types. However, in the absence of appropriate
cues, pellets gradually diminished in size, DNA content,
and the major chondrogenic ECM proteins. While
chondrocytes and MSCs achieved biochemically equiva-
lent sGAG content, there were notable differences in the
spatial distributions of the ECM proteins resulting in
heterogeneous, ﬁbrous tissue formation in the MSC pel-
lets, MSCs did not maintain SOX9 expression and
appeared to have progressed to a hypertrophic pheno-
type favoring the continued use of primary chondro-
cytes in cartilage cell therapy trials. Transduced cells
had a reduced chondrogenic response compared with
parental cells and in conﬁrmation of previous two-
dimensional (2D) results they do not represent a suitable
replacement for primary cells. However, interestingly
there were indications, such as the sustained differen-
tial response to MM and PChM, SOX9 expression,
and in particular the improvement seen by transferring
OK3H from a 2D to a 3D environment, which suggested
that the transduction while clearly signiﬁcantly impact-
ing upon the cells’ chondrogenic potential had not com-
pletely abrogated the chondrogenic response, and future
optimization of the immortalization process may pro-
duce cell lines with much greater in vitro utility.
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